Together, these studies indicate that the maintenance of PGC-1α levels in PD could offer neuroprotective therapeutic opportunities in PD (Zheng et al., 2010; Clark et al., 2011; Shin et al., 2011; Eschbach et al., 2015; Su et al., 2015). The gene discussed is PPARGC1A; the disease is Parkinson disease.